Finance
Biotechnology announces transition quarter financial results
Published in Obesity and Diabetes Week, March 7th, 2005
The 3-month period ended December 31, 2004, represents a transition quarter for the company as it has changed its fiscal year-end from September 30th to December 31st, to align its operating cycle with that of its alliance partners and its industry sector.
The company reported a net loss of $48.4 million (or $1.02 per share) for the 3 months ended December 31, 2004, compared with a net loss of $40.1 million (or $1.03 per share) in the comparable prior year period. On a non-GAAP basis, excluding certain charges and adjustments,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetic Nephropathy
Hypertriglyceridemia implicated in diabetic nephropathy - Diabetic Neuropathy
Neural redox stress in type 2 diabetes and neuropathy reviewed - Obesity and Diabetes
Obesity, bariatric surgery, and type 2 diabetes reviewed - Obesity and Diabetes
Protein kinase C interactions in adipocytes regulate glucose uptake - Obesity and Diabetes
Signal pathway regulating plasminogen activator inhibitor identified - Allergy and Immunology
Interleukin-10 gene therapy protects islet grafts after transplantation - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
